Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36125   clinical trials with a EudraCT protocol, of which   5941   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000750-35
    Sponsor's Protocol Code Number:BP39055
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2016-06-16
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-000750-35
    A.3Full title of the trial
    A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS.
    ESTUDIO DE CONTINUIDAD EN DOS PARTES, MULTICÉNTRICO, ALEATORIZADO, CONTROLADO POR PLACEBO Y CON DOBLE ENMASCARAMIENTO PARA INVESTIGAR LA SEGURIDAD, LA TOLERABILIDAD, LA FARMACOCINÉTICA, LA FARMACODINÁMICA Y LA EFICACIA DE RO7034067 EN PACIENTES CON ATROFIA MUSCULAR ESPINAL DE TIPOS 2 Y 3
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy patients
    Estudio para investigar la seguridad, tolerabilidad, farmacocinetica, farmacodinamia y eficacia de RO7034067 en pacientes con atrofia muscular espinal tipo 2 y 3.
    A.4.1Sponsor's protocol code numberBP39055
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/284/2017
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. Hoffmann-La Roche Ltd
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF.Hoffmann-La Roche Ltd
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number+34913257300
    B.5.6E-mailspain.start_up_unit@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRO7034067
    D.3.2Product code RO7034067/F12
    D.3.4Pharmaceutical form Powder for oral solution
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNn.a
    D.3.9.1CAS number 1825352-65-5
    D.3.9.2Current sponsor codeRO7034067/F06
    D.3.9.4EV Substance CodeSUB179686
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRO7034067
    D.3.2Product code RO7034067/F13
    D.3.4Pharmaceutical form Powder for oral solution
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNn.a
    D.3.9.1CAS number 1825352-65-5
    D.3.9.2Current sponsor codeRO7034067/F07
    D.3.9.4EV Substance CodeSUB179686
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPowder for oral solution
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPowder for oral solution
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Spinal Muscular Atrophy (SMA)
    Atrofia Muscular Espinal (AME)
    E.1.1.1Medical condition in easily understood language
    Spinal Muscular Atrophy, a genetic progressive neuromuscular disease characterized by profound weakness and muscle atrophy that is the leading genetic cause of death in babies and toddlers.
    Attrofia muscular espinal es una enfermedad genética neuromuscular progresiva caracterizada por profunda debilidad y atrofia muscular que es la causa genética principal de muerte en bebes e infantes
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10041582
    E.1.2Term Spinal muscular atrophy
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Part 1:
    •To evaluate the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7034067 in patients with Type 2 and Type 3 (ambulant or non-ambulant) SMA, and to select the dose for Part 2 of the study

    Part 2:
    •To evaluate efficacy of RO7034067 compared to placebo in terms of motor function in Type 2 and non-ambulant Type 3 SMA patients, as assessed by the change from baseline in the total score of the Motor Function Measure (MFM) at 12 months
    Parte 1:
    •Evaluar la seguridad, la tolerabilidad, la farmacocinética (FC) y la farmacodinámica (FD) de RO7034067 en pacientes con atrofia muscular espinal (AME) de tipos 2 y 3 (con o sin capacidad deambulatoria) y seleccionar la dosis para la parte 2 del estudio.
    Parte 2:
    •Evaluar la eficacia de RO7034067 en comparación con el placebo respecto de la función motora en pacientes con AME de tipo 2 y de tipo 3 sin capacidad deambulatoria, mediante la evaluación del cambio respecto del valor basal en la puntuación total de la escala de medición de la función motora (MFM) a los 12 meses.
    E.2.2Secondary objectives of the trial
    Part 2:To investigate
    •the PK/PD relationship of RO7034067 by PK/PD modeling
    •the efficacy of 12 month treatment with RO7034067 in terms of motor function as assessed by the Hammersmith Functional Motor Scale Expanded (HFMSE), the revised upper limb module (RULM) and responder analyses of the MFM
    •the efficacy of 12 month treatment with RO7034067 in terms of respiratory function as assessed by Sniff nasal inspiratory pressure (SNIP) and, in patients aged 6 years and older,by Maximal Inspiratory Pressure (MIP),Maximal Expiratory Pressure (MEP),Forced vital capacity (FVC),Forced expiratory volume (FEV1) and Peak cough flow (PCF)
    •proportion of patients who experience a pre-specified disease related adverse event by Month 12
    •The efficacy of 12 month treatment with RO7034067 in terms of global health status as assessed by the Clinical Global Impression of Change (CGI-C) and independence, as measured by the SMA Independence Scale (SMAIS)
    •the safety and tolerability of RO7034067
    Parte 2: Investigar
    •La relación FC/FD de RO7034067 mediante la generación de modelos FC/FD
    •La eficacia del tratamiento durante 12 meses con RO7034067 respecto de la función motora mediante la evaluación en función de HFMSE, de la RULM y los análisis de respuesta de la MFM.
    •La eficacia del tratamiento durante 12 meses con RO7034067 respecto de la función respiratoria mediante la SNIP y, en pacientes con edad igual o superior a 6 años, de la presión PIM, la presión espiratoria máxima (PEM), la CVF, el volumen espiratorio forzado en 1 segundo (VEF1) y el flujo pico de tos (FPT).
    •Proporción de pacientes que sufran un acontecimiento adverso predeterminado relacionado con la enfermedad hasta el mes 12
    •Eficacia del tratamiento durante 12 meses con RO7034067 respecto del estado general de salud mediante la evaluación en función de la Escala CGI-C Escala de independencia SMA (SMAIS).
    •Investigar la seguridad y la tolerabilidad del tratamiento con RO7034067.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Males and females 2 to 25 years of age inclusive
    - For Part 1: Type 2 or 3 SMA ambulant or non-ambulant. For Part 2: Type 2 or 3 SMA non-ambulant.
    Non-ambulant is defined as not having the ability to walk unassisted for 10 m or more
    - Confirmed diagnosis of 5q-autosomal recessive SMA
    - Negative blood pregnancy test at screening and agreement to comply with measures to prevent pregnancy and restrictions on sperm donation
    -Varones y mujeres de 2 a 25 años inclusive
    -Para la parte 1: AME de tipos 2 o 3 con o sin capacidad deambulatoria.
    Para la parte 2: AME de tipo 2 o AME de tipo 3 sin capacidad deambulatoria. La ausencia de capacidad deambulatoria se define como la incapacidad de andar sin ayuda a lo largo de 10 m o más.
    -Diagnóstico confirmado de AME con cromosoma 5q autosómico recesivo, lo que abarca:
    -Prueba de embarazo en sangre negativa en la selección y compromiso de cumplir las medidas para evitar el embarazo y las restricciones sobre la donación de semen
    E.4Principal exclusion criteria
    - Concomitant or previous participation in any investigational drug or device study within 90 days
    prior to screening, or 5 half-lives of the drug, whichever is longer
    - Concomitant or previous administration of a SMN2 targeting antisense oligonucleotide, SMN2 splicing modifier or gene therapy either in a clinical study or as part of medical care.
    - Any history of cell therapy
    - Hospitalization for a pulmonary event within the last 2 months or planned at time of screening
    - Surgery for scoliosis or hip fixation in the one year preceding screening or planned within the next 18 months
    - Unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system diseases as considered to be clinically significant by the Investigator
    - Presence of clinically significant ECG abnormalities before study drug administration from average of triplicate measurement or cardiovascular disease indicating a safety risk for patients as determined by the Investigator
    - History of malignancy if not considered cured
    - Significant risk for suicidal behavior, in the opinion of the Investigator as assessed by the C-SSRS (>6 years of age)
    - Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to first dose administration
    - Any Organic cation transporter (OCT)-2 and multidrug and toxin extrusion (MATE) substrates within 2 weeks before dosing
    - Use of the following medications within 90 days prior to randomization: riluzole, valproic acid, hydroxyurea, sodium phenylbutyrate, butyrate derivatives, creatine, carnitine, growth hormone, anabolic steroids, probenecid, agents anticipated to increase or decrease muscle strength, agents with known or presumed histone deacetylase (HDAC) inhibitory effect, and medications with known phototoxicity liabilities
    - Recently initiated treatment (within < 6 months prior to randomization) with oral salbutamol or another 2-adrenergic agonist taken orally
    - Any prior use of chloroquine, hydroxychloroquine, retigabin, vigabatrin or thioridazine, is not allowed.
    - Clinically significant abnormalities in laboratory test results
    - Donation or loss of blood >= 10% of blood volume within three months prior to screening
    - Ascertained or presumptive hypersensitivity (e.g., anaphylactic reaction) to RO7034067 or to the constituents of its formulation
    - Recent history (less than one year) of ophthalmological diseases
    - Patients requiring invasive ventilation or tracheostomy
    -Participación previa o concomitante en cualquier estudio con un fármaco o dispositivo experimental en un plazo de 90 días antes de la selección o 5 semividas del fármaco, lo que sea más largo.
    -Cualquier antecedente de terapia celular.
    -Hospitalización a causa de un acontecimiento pulmonar en los últimos 2 meses o que esté prevista en el momento de la selección.
    -Intervención quirúrgica para tratar la escoliosis o de fijación de cadera en el año anterior a la selección o que esté prevista en los 18 meses siguientes.
    -Afecciones gastrointestinales, renales, hepáticas, endocrinas o cardiovasculares inestables que el investigador considere significativas desde el punto de vista clínico.
    -Presencia de anomalías en el ECG significativas desde el punto de vista clínico antes de la administración del fármaco con respecto al promedio de la medición por triplicado o enfermedad cardiovascular que pongan de manifiesto un riesgo para la seguridad de los pacientes, según determine el investigador.
    -Antecedentes de neoplasia maligna que no se considere curada.
    -Riesgo significativo de conducta suicida, en opinión del investigador, evaluada mediante el cuestionario C-SSR (>6 años).
    -Cualquier enfermedad importante un mes antes de las pruebas de la selección o cualquier enfermedad febril en el plazo de una semana antes de la selección y hasta la administración de la primera dosis.
    -Cualquier sustrato de OCT-2 y MATE en un plazo de 2 semanas antes de la administración.
    -El uso de los siguientes medicamentos en un plazo de 90 días antes de la aleatorización: riluzol, ácido valproico, hidroxiurea, fenilbutirato de sodio, derivados del butirato, creatina, carnitina, hormona del crecimiento, esteroides anabólicos, probenecid, fármacos que se prevé que aumenten o disminuyan la fuerza muscular, fármacos con efectos conocidos o supuestos de inhibición de la histona deacetilasa (HDAC) y fármacos con efectos fototóxicos conocidos.
    -El tratamiento iniciado de forma reciente (en un plazo 6 meses antes de la aleatorización) con salbutamol oral u otro agonista adrenérgico β2 por vía oral
    -Cualquier uso previo de cloroquina, hidroxicloroquina, retigabina, vigabatrina o tioridazina no está permitido.
    -Anomalías significativas desde el punto de vista clínico en los resultados de pruebas analíticas
    -Donación de sangre o pérdida >=10 % del volumen de sangre en un plazo de tres meses antes de la selección.
    -Hipersensibilidad conocida o presunta (por ejemplo, reacción anafiláctica) a RO7034067 o a los componentes de su formulación
    -Enfermedades o afecciones concomitantes o tratamientos que pudieran interferir con la realización del estudio o que, en opinión del investigador, supongan un riesgo inaceptable para el paciente en este estudio.
    -Antecedentes recientes (menos de un año) de enfermedades oftalmológicas
    -Pacientes que precisen de ventilación invasiva o de una traqueotomía.
    E.5 End points
    E.5.1Primary end point(s)
    Part 1
    1. Incidence of adverse events and serious adverse events
    2. Maximum plasma concentration (Cmax) of RO7034067
    3. Area under the curve (AUC) of RO7034067
    4. Concentration at the end of a dosing interval (Ctrough) of RO7034067

    Part 2
    5. Change from baseline in the total MFM 32 score at Month 12
    Parte 1
    1. Incidencia de acontecimientos adversos y acontecimientos adversos graves
    2. Concentración máxima plasmática (Cmax) de RO7034067
    3. Area bajo la curva (AUC) de RO7034067
    4. Concentración al final de un intervalo de dosificiacion (Ctrough) de RO7034067

    Parte 2
    5. Cambio desde basal en la puntuación MFM total 32 en el mes 12
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. Up to 24 months
    2-4. Days 1, 7, 14, 28, 56, 120, 246, 365, 490, 609, and 729
    5. Baseline (Day -1) and Month 12
    1. Hasta un máximo de 24 meses
    2-4 Dias 1,7, 14, 28, 56, 120, 246, 365, 490, 609 y 729
    5. Basal (dia -1) y mes 12.
    E.5.2Secondary end point(s)
    Part 2
    1.SMN2 mRNA in blood
    2.SMN protein levels in blood
    3.Change from baseline in total score of HFMSE at Month 12
    4.Change from baseline in the total score of the revised upper limb module (RULM) at Month 12
    5.Proportion of patients who achieve stabilization or improvement (i.e., a change from baseline >= 0) on the total MFM score at Month 12
    6.Proportion of patients who achieve an improvement of at least one standard error of measurement (SEM calculated at baseline) on the total MFM score at Month 12.
    7.Change from baseline in the MFM domain scores of D1, D2, D3 and the total combined score of (D1 + D2) at Month 12.
    8.Change from baseline in the best SNIP (expressed as a percentage of the predicted value) at Month 12.
    9.Change from baseline in the best MIP at Month 12.
    10.Change from baseline in the best MEP at Month 12
    11.Change from baseline in FEV1 in patients aged 6 to 25 years at Month 12
    12.Change from baseline in FVC in patients aged 6 to 25 years at Month 12.
    13.Change from baseline in the peak cough flow (PCF) in patients aged 6 to 25 years at Month 12.
    14.Change from baseline in the Total Score of the caregiver-reported SMA independence Scale (SMAIS) at Month 12.
    15.Change from baseline in the Total score of the patient-reported SMA independence scale (SMAIS) at Month 12
    16.Proportion of patients rated by clinicians as no change or improved in the Clinical Global Impression of Change (CGI-C) Scale at Month 12 (Part 2 only).
    17.Proportion of patients rated by clinicians as improved in the Clinical Global Impression of Change (CGI-C) Scale at Month 12.
    18.Proportion of patients who experience at least one disease related adverse event by Month 12
    19.Number of disease-related adverse events per patient-year at Month 12
    20.PedsQL 4.0 Generic Core scale(Part 1 only)
    21.PedsQL 3.0 Neuromuscular module (Part 1 only)
    Parte 2
    1. SMNA 2 mRNA en sangre
    2. Niveles de proteina de SMN en sangre
    3. Cambio desde basal en la puntuación local de HFMSE en el mes 12
    4.Cambio desde basal en la puntuacion total del RULM en el mes 12
    5.Proporcion de pacientes que alcanzan la estabilización o mejora (es decir, cambio desde basal >= 0) en la puntuacion total del MFM en el mes 12.
    6.Proporcion de pacientes que alcanzan una mejoria de al menos una medida standart de error (SEM calculada en basal) en la puntuacion total de MFM en el mes 12.
    7.Cambio desde basal en los dominios D1, D2 y D3 de la puntuación del MFM y la puntuacion total combinada de (D1+ D2) en el mes 12.
    8.Cambio desde basal en el mejor SNIP (eexpresado como porcentaje del valor predictivo) en el mes 12.
    9.CCambio desde basal en el mejor MIP en el mes 12.
    10.Change from baseline in the best MEP at Month 12
    11.Cambio desde basal en el FEV1 en pacientes entre 6 y 25 años en el mes 12.
    12.Cambio desde basal en el FVC de pacientes entre 6 y 25 años en el mes 12.
    13.Cambio desde basal en el PCF en pacientes entre 6 y 25 años en el mes 12.
    14.Cambio desde basal en la puntuacion total del SMAIS del cuidador en el mes 12
    15.Cambio desde basal en la puntuacion total del SMAIS del paciente en el mes 12
    16.Proporcion de pacientes clasificados por el medico como no cambio o mejora en la escala Clinical Global Impression of Change (CGI-C) en el mes Mes 12 (Solo Parte 2).
    17. Proporcion de pacientes clasificados por el medico como mejora en la escala Clinical Global Impression of Change (CGI-C) en el mes 12.
    18.Proporcion de pacientes que experimentan al menos una enfermedad relacionada con acontecimiento adverso hasta el mes 12.
    19.Proporcion de acontecimientos adversos relacionados con la enfermedad por paciente en el mes 12.
    20.Escala PedsQL 4.0 Generic Core (Solo Parte 1)
    21.Modulo PedsQL 3.0 Neuromuscular (Solo Parte 1)
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Part 1: Days -1, 1, 7, 14, 28, 120, 246, 365, 729; Part 2: Days -1, 1, 7, 28, 120, 246, 365, 729
    2. Part 1: Days -1, 7, 14, 28, 120, 246, 365, 729; Part 2: Days -1, 7, 28, 120, 246, 365, 729
    3-17. Baseline (Day-1) and Month 12
    18-19. Up to Month 12
    20-21. Week 35, Week 62, at early withdrawal
    1. Parte 1: Dias -1, 1, 7, 14, 28, 120, 246, 365, 729; Parte 2: Dias -1, -1, 7, 28, 120, 246, 365, 729
    2. Parte 1: Dias -1, 7, 14, 28, 120, 246, 365, 729; Parte 2: Dias -1, 7, 28, 120, 246, 365, 729
    3-17. Basal (dia -1) y mes 12
    18-19. Hasta el mes 12 como máximo
    20-21. Semana 35, 62 y retirada prematurura
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    genetic testing
    testing genetico
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    2 part design
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA31
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Belgium
    Brazil
    Bulgaria
    Canada
    China
    Croatia
    France
    Germany
    Hungary
    Italy
    Japan
    Mexico
    Poland
    Romania
    Russian Federation
    Serbia
    Spain
    Switzerland
    Turkey
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Since this study includes an OLE phase for all enrolled patients, it will continue until RO7034067 is commercially available in the patient’s country, or as per local regulation, or per the Sponsor’s decision to terminate RO7034067 development. In any case the study will not exceed 4 years (or less as per country specific requirements) after the last patient is enrolled in the study.
    The end of this study is defined as the date when the last patient last visit (LPLV) occurs.
    Como el ensayo incluye una Fase OLE para todos los pacientes incluidos, continuará hasta que RO7034067 este disponible comercialmente en el país del paciente, o según legislación local o por decisión del promotor de terminar el desarrollo de RO7034067. En cualquier caso, el estudio no excederá 4 años (o menos por requerimientos de cada país) después de que el ultimo paciente sea incluido
    El final del estudio se define como la fecha cuando la ultima visita del ultimo paciente (UVUP) ocurra
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 185
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 123
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 62
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 34
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Pediatric patients may provide according to local regulation informed assent
    informed consent for study participation will be obtained from parents or legal guardian
    Los pacientes pediátricos pueden proporcionar asentimiento informado de acuerdo a su regulación local. El consentimiento informado para la participación en el estudio será obtenida de los padres o tutores legales
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 150
    F.4.2.2In the whole clinical trial 219
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    A patient will be eligible to receive study drug after completing the study if all of the following conditions are met: The patient has a life-threatening or severe medical condition and requires continued study drug treatment for his or her well-being/There are no appropriate alternative treatments available to the patient/The patient and his/her doctor comply with and satisfy any legal or regulatory requirements that apply to them. See furher details in section 4.4.4 of the protocol.
    Un paciente será elegible para recibir fármaco del estudio después de completarlo si todas las condiciones siguientes se cumplen: El paciente tiene una enfermedad severa o amenazante para la vida que requiere tratamiento continuo con fármaco del estudio para su bienestar/No hay alternativas de tratamiento apropiadas disponibles para el paciente/El paciente y su medico cumplen y satisfacen cualquier requerimiento legal o regulatorio que les aplica. Ver detalles en la sección 4.4.4 del protocolo
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-03-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-02-16
    P. End of Trial
    P.End of Trial StatusOngoing
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA